IMMUNE T CELLS REACTIVE AGAINST HUMAN T-CELL LEUKAEMIA/LYMPHOMA VIRUS
The Lancet, ISSN: 0140-6736, Vol: 323, Issue: 8378, Page: 649-652
1984
- 9Citations
- 5Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef6
- Captures5
- Readers5
Article Description
Six patients with malignant disorders associated with human T-cell leukaemia/ lymphoma virus (HTLV) were studied to see whether long-term cultures of immune T cells reactive against HTLV-infected tumour cells could be achieved. Immune T-cell lines could not be developed from the cells of five patients who died or eventually had a relapse of disease, but in one patient who had an unusually long remission of his disease after therapy, immune T-cell lines were propagated that could produce their own T-cell growth factor and proliferate upon stimulation with autologous tumour cells and also specifically lyse HTLV-infected target cells. These immune T cells recognised the presence of circulating HTLV-bearing neoplastic cells in another patient with HTLV-associated T-cell leukaemia, who had been in clinical remission after chemotherapy when this study started, thereby providing early evidence of relapse.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S014067368492169X; http://dx.doi.org/10.1016/s0140-6736(84)92169-x; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0021322066&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/6142349; http://linkinghub.elsevier.com/retrieve/pii/S014067368492169X; http://api.elsevier.com/content/article/PII:S014067368492169X?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S014067368492169X?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S014067368492169X; http://dx.doi.org/10.1016/s0140-6736%2884%2992169-x; https://dx.doi.org/10.1016/s0140-6736%2884%2992169-x
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know